Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06718049

Role of Interleukin 18 (IL-18) and Interleukin 18 Binding Protein (IL-18BP) in the Diagnostic Work-up of Systemic Juvenile Idiopathic Arthritis and Autoinflammatory Diseases: Possible Biomarkers in the Differential Diagnosis of Other Febrile Diseases

Literature data suggest that elevated blood values of IL-18 and IL-18 Binding Protein and alterations in their ratio may be significantly correlated with various autoinflammatory diseases, such as systemic juvenile idiopathic arthritis, recurrent autoinflammatory fevers etc. In this view, the clinical implication of this observational, prospective, single-centre, non-pharmacological study will be the definition of new laboratory markers that may be useful in the early differential diagnosis of certain rare and serious paediatric diseases.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

2 year–18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Bologna, 40138, Italy

Location contact

Angela Miniaci

PRINCIPAL_INVESTIGATOR

Angela Miniaci, MD

CONTACT

[email protected]

00390512144811

About this study

The primary aim of this study is to investigate the role of IL-18 and IL-18 Binding Protein as biomarkers of systemic Juvenile Idiopathic Arthritis and recurrent autoinflammatory fevers, while the secondary one is to investigate the superiority of IL-18 and IL-18 Binding Protein over other cytokines and inflammatory indexes in the differential diagnosis of systemic Juvenile Idiopathic Arthritis and recurrent fevers of an autoinflammatory nature.

The study will enroll patients referred to the Pediatric Rheumatology Outpatient Clinic of the Pediatrics Unit, IRCCS Azienda Ospedaliero-Universitaria of Bologna, Italy, for suspected Juvenile Idiopathic Arthritis or suspected recurrent fever/self-inflammatory disease.

Patients will be enrolled during the acute phase of the disease and, prior to the start of immunosuppressive therapy (i.e. corticosteroids, colchicine, biological drugs), a blood sample will be taken for haematochemical investigations, according to clinical practice, as well as an additional blood sample for the assay of IL-18 and IL-18 Binding Protein.

The following variables will be considered for each patient: demographic data; key clinical features; haemochromocytometric test; liver and kidney function tests; indexes of inflammation and acute phase proteins; inflammatory cytokines panel; serum values of IL-18 and IL-18 Binding Protein.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age between 2 years and 18 years;
  • Being affected by 1 of the following: Juvenile Idiopathic Arthritis; recurrent fever/ autoinflammatory disease; rheumatic disease; severe infectious diseases (sepsis, meningitis, urinary tract infection, lower respiratory tract infection);
  • Obtaining informed consent from parents/legal guardians of paediatric patients.

Exclusion criteria

  • Patients in whom the suspicion of rheumatic disease is based on a finding of subclinical carditis or chorea.

Treatment and study plan

Primary outcomes

  1. Serum levels of IL-18, and IL-18BP

    Time frame: at T0 - T1(3 months) - T2(12 months)

    pg/mL

Secondary outcomes

  1. Serum levels of inflammatory cytokines

    Time frame: at T0 - T1(3 months) - T2(12 months)

    IL-6; IL-8; TNF alpha; IL-12p70; IL-1 beta; IL-10 (pg/mL)

  2. Serum levels of acute phase proteins

    Time frame: at T0 - T1(3 months) - T2(12 months)

    C-reactive protein (mg/dL); amyloid A protein (mg/dL); ferritin (ng/dL); transferrin (mg/dL); fibrinogen (mg/dL)

Study contacts

Contact information is provided by the study sponsor or research team.

Angela Miniaci, MD

CONTACT

[email protected]

00390512144811

Sponsors and collaborators

Lead sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Other

Registry information

Important dates

Study start
2027
Primary completion
2027
Study completion
2027
First posted
Dec 5, 2024
Registry last updated
Mar 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.